A vaccine that protects against one of the main common cold viruses has been shown to be safe and effective in a clinical trial and could be available by 2024.

Respiratory syncytial virus (RSV) is so contagious that more than 90 per cent of people have experienced their first infection by the age of 2. It usually causes cold symptoms but can lead to severe illness in young children and older people. Globally, around 60,000 children …